The U.S. Food and Drug Administration (FDA) has approved capivasertib in combination with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naïve or androgen pathway modulation-sensitive prostate cancer. The approval introduces a new targeted treatment option for patients with a particularly aggressive form of the disease and represents an important advancement in precision oncology.
The newly approved regimen combines capivasertib with the established hormonal therapies abiraterone and prednisone. Patients must have PTEN-deficient tumors confirmed through an FDA-authorized diagnostic test before beginning treatment. Additionally, the FDA approved the VENTANA PTEN (SP218) RxDx Assay as a companion diagnostic to identify eligible patients accurately and support personalized treatment decisions.
The approval is based on results from the Phase III CAPItello-281 clinical trial, which evaluated capivasertib in patients with newly diagnosed PTEN-deficient metastatic prostate cancer. The randomized, double-blind, placebo-controlled study enrolled 1,012 adults across multiple international clinical sites. Researchers compared capivasertib plus abiraterone against placebo plus abiraterone, while all participants received androgen deprivation therapy throughout the study.
The trial achieved its primary endpoint by demonstrating a statistically significant improvement in radiographic progression-free survival (rPFS). Patients receiving capivasertib achieved a median rPFS of 33.2 months, compared with 25.7 months among patients receiving placebo alongside abiraterone. As a result, the treatment reduced the risk of disease progression or death by 19%, highlighting its potential to delay cancer advancement in a difficult-to-treat patient population.
PTEN deficiency affects approximately one-quarter of patients suffering from hormone-sensitive metastatic prostate cancer and is linked with negative patient outcomes. Healthcare professionals require treatments that focus on addressing molecular mechanisms responsible for PTEN deficiency-related cancers. The approval of capivasertib addresses this unmet medical need by inhibiting the AKT signaling pathway, which becomes activated when PTEN function is lost.
The need for innovative treatment options remains significant as prostate cancer continues to place a substantial burden on healthcare systems. According to the Centers for Disease Control and Prevention (CDC), 266,307 new prostate cancer cases were reported in the United States in 2023. Furthermore, 34,815 males in the United States died from prostate cancer in 2024. These statistics underscore the ongoing impact of the disease and reinforce the importance of introducing targeted therapies such as capivasertib for patients with high-risk tumor characteristics.
Researchers and clinicians view the approval as a significant step towards broader implementation of biomarker-driven treatment strategies in prostate cancer. While targeted therapies have revolutionized treatment paradigms in many cancer types, treatment options for patients with PTEN-deficient metastatic prostate cancer have been limited. Thus, capivasertib may allow physicians to individualize treatment plans based on molecular profiles rather than relying on traditional hormonal therapies.
Moreover, the approval reflects the broader shift toward precision medicine in oncology. By identifying patients who can be identified by unique biomarkers, therapies can be chosen that are designed to attack the biological causes of disease. Thus, capivasertib will serve as an effective personalized medicine, which could lead to improved disease management and patient outcomes.
The recommended dose of capivasertib is 400 mg orally twice daily, approximately 12 hours apart. The patients are placed on a treatment schedule of four consecutive treatment days followed by three days off therapy. Meanwhile, abiraterone is administered daily at a dose of 1,000 milligrams with prednisone. Patients should also receive concurrent gonadotropin-releasing hormone therapy or have previously undergone bilateral orchiectomy.
This approval also highlights the increased involvement of molecular diagnostics in cancer. With the increasing use of biomarker assays in clinical settings, drugs like capivasertib can be used in identifying patients most likely to benefit from targeted intervention. This personalized approach may improve treatment outcomes while supporting more efficient and effective healthcare delivery.
Prostate cancer remains among the most frequently detected forms of cancer among men; the availability of capivasertib represents an exciting development for patients who suffer from PTEN-deficient metastatic disease. While additional survival data are still needed, the FDA’s decision offers clinicians an important new tool to delay disease progression and advance precision treatment strategies in prostate cancer management.
